Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | EVP & CHIEF FINANCIAL OFFICER | March 02, 2026 | March 04, 2026 |
| Boundless Bio, Inc.BOLD · Entity 7063 | Director | June 15, 2026 | June 15, 2026 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Financial Officer | May 01, 2019 | May 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 170,700 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 5,565 · Balance 170,700 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Boundless Bio, Inc.
Report date June 15, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2036-06-14 | Direct | 32,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 32,000 · Balance 32,000 F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.
CHINOOK THERAPEUTICS, INC.
Report date May 01, 2019 · Filed May 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 135,155 |
Ending reported balance
After 2019-05-01 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-05-01 · Exercise / conversion · Acquired 4,226 · Balance 139,381 Row 2 · 2019-05-01 · Sale · Disposed 4,226 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2019-05-01 · Exercise / conversion · Acquired 2,232 · Balance 137,387 Row 4 · 2019-05-01 · Sale · Disposed 2,232 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2019-05-01 · Exercise / conversion · Acquired 12,144 · Balance 147,299 Row 6 · 2019-05-01 · Sale · Disposed 12,144 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2023-11-26 | Direct | 42,258 |
Reported balance
After 2019-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-01 · Exercise / conversion · Disposed 4,226 · Balance 42,258 F3: The shares subject to the Option are fully vested and immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 22,320 |
Reported balance
After 2019-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-05-01 · Exercise / conversion · Disposed 2,232 · Balance 22,320 F3: The shares subject to the Option are fully vested and immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2025-01-09 | Direct | 121,440 |
Reported balance
After 2019-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-05-01 · Exercise / conversion · Disposed 12,144 · Balance 121,440 F3: The shares subject to the Option are fully vested and immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The shares subject to the Option are fully vested and immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 15, 2026 23:28 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001193125-26-271453 · ownership.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 5,565 | $5.42 | $30,162.30 |
DisclosureSEC source: 0001465994-26-000003 · form4-03042026_040334.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,700 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:03 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001465994-26-000002 · form4-02242026_120245.xml · derivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-02-19 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:03 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001465994-26-000002 · form4-02242026_120245.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,265 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 7,851 | $5.11 | $40,118.61 |
DisclosureSEC source: 0001465994-26-000001 · form4-02202026_040201.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,765 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $4.925 to $5.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:20 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,117 | $2.58 | $2,881.86 |
DisclosureSEC source: 0001415889-25-019837 · form4-07162025_040704.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,616 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $2.58 to $2.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 21:15 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-25-089082 · ownership.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-22 F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 272,575 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001415889-25-006193 · form4-03032025_090309.xml · derivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,575 Underlying: Common Stock · 272,575 shares Expires 2034-02-27 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 27, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:48 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 6,912 | $2.92 | $20,183.04 |
DisclosureSEC source: 0001415889-25-004886 · form4-02202025_090202.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,770 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $2.79 to $3.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,786 | $2.98 | $5,322.28 |
DisclosureSEC source: 0001415889-25-004433 · form4-02182025_040205.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,682 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $2.89 to $3.015, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:48 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,104 | $6.03 | $6,657.12 |
DisclosureSEC source: 0001415889-24-019678 · form4-07172024_080740.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,468 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $5.97 to $6.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 5,514 shares acquired on May 15, 2024, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 13,219 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038703 · ownership.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,219 Underlying: Common Stock · 13,219 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| February 27, 2024 Filed Mar 3, 2025 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 44,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006193 · form4-03032025_090309.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,733 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 27 of each year, with the first 1/3rd vesting on February 27, 2026. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:31 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 2,593 | $5.53 | $14,339.29 |
DisclosureSEC source: 0001415889-24-004623 · form4-02212024_040210.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,058 F2 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: This transaction was executed in multiple trades in prices ranging from $5.39 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:31 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001415889-24-004623 · form4-02212024_040210.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-02-16 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:31 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004623 · form4-02212024_040210.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,651 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:54 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,809 | $5.54 | $10,021.86 |
DisclosureSEC source: 0001415889-24-003855 · form4-02152024_120234.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,651 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $5.33 to $5.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 29,392 RSUs. Read SEC document |
| July 11, 2023 Filed Jan 23, 2024 21:57 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,057 | $3.84 | $4,054.76 |
DisclosureSEC source: 0001209191-24-002072 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,460 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades in prices ranging from $3.72 to $3.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 33,559 RSUs. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:26 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 77,050 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001567619-23-003424 · doc1.xml · derivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,050 Underlying: Common Stock · 77,050 shares Expires 2033-02-16 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:26 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 18,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003424 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,517 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2024. F2 · balance_after: Includes 36,684 RSUs. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 23:59 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 166 | $6.30 | $1,046.30 |
DisclosureSEC source: 0001567619-23-003094 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,542 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · balance_after: Includes 17,709 restricted stock units. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 23:59 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,742 | $6.31 | $10,988.71 |
DisclosureSEC source: 0001567619-23-003094 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,708 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades in prices ranging from $6.15 to $6.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 7,575 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 15, 2022. F4 · balance_after: Includes 17,709 restricted stock units. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 22:48 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001567619-22-013991 · doc1.xml · derivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-07-11 F3 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 22:48 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013991 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,875 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on July 11th of each year, with the first 1/3rd vesting on July 11, 2023. F2 · balance_after: Includes 21,875 RSUs. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:36 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.94 | $0.00 |
DisclosureSEC source: 0001567619-22-004612 · doc1.xml · derivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-11 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:36 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004612 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 11 of each year, with the first 1/3rd vesting on February 11, 2023. F2 · balance_after: Includes 12,500 RSUs. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 22:35 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001567619-21-017165 · doc1.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,793 Underlying: Common Stock · 3,500 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 3, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 22:35 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 3,500 | $20.01 | $70,033.60 |
DisclosureSEC source: 0001567619-21-017165 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 22:35 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionCommon Stock | 3,500 | $7.49 | $26,209.75 |
DisclosureSEC source: 0001567619-21-017165 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 22:01 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001567619-21-011453 · doc1.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,293 Underlying: Common Stock · 3,500 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 3, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 22:01 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 3,500 | $22.24 | $77,835.10 |
DisclosureSEC source: 0001567619-21-011453 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.78 to $22.67, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 22:01 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionCommon Stock | 3,500 | $7.49 | $26,209.75 |
DisclosureSEC source: 0001567619-21-011453 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:31 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001567619-21-006986 · doc1.xml · derivative · entry 5 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,793 Underlying: Common Stock · 5,000 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 3, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:31 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,800 | $29.16 | $52,493.22 |
DisclosureSEC source: 0001567619-21-006986 · doc1.xml · nonDerivative · entry 4 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades in prices ranging from $28.98 to $29.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:31 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,800 | $28.43 | $51,174.72 |
DisclosureSEC source: 0001567619-21-006986 · doc1.xml · nonDerivative · entry 3 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $27.97 to $28.965, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:31 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 1,400 | $27.51 | $38,508.54 |
DisclosureSEC source: 0001567619-21-006986 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $26.94 to $27.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:31 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionCommon Stock | 5,000 | $7.49 | $37,442.50 |
DisclosureSEC source: 0001567619-21-006986 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:05 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $30.07 | $0.00 |
DisclosureSEC source: 0001567619-21-005221 · doc1.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 25, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:18 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 2,000 | $17.00 | $34,000.00 |
DisclosureSEC source: 0001567619-20-013818 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,144 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · derivative · entry 9 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,440 Underlying: Common Stock · 12,144 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,232 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · derivative · entry 8 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,320 Underlying: Common Stock · 2,232 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,226 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · derivative · entry 7 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,258 Underlying: Common Stock · 4,226 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 12,144 | $4.20 | $51,009.66 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 6 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 12,144 | $1.45 | $17,608.80 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 5 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 2,232 | $4.20 | $9,375.29 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 4 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 2,232 | $1.00 | $2,232.00 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 3 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,226 | $4.20 | $17,750.89 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 4,226 | $0.82 | $3,465.32 |
DisclosureSEC source: 0001567619-19-009775 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,144 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · derivative · entry 9 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,584 Underlying: Common Stock · 12,144 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,232 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · derivative · entry 8 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,552 Underlying: Common Stock · 2,232 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.